PFEPfizerRunning, no new patients
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 854 (final count)
- Started
- Mar 25, 2022
- Main results expected
- Aug 4, 2027
- Fully finished
- Oct 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival
Measured over: Assessed for up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05317416 · record last updated 2026-04-16 · checked 2026-11-09 15:42 UTC